Research programme: vasopressin 1b antagonists - Merck/Sanofi Aventis
Alternative Names: ORG 52186; SCH 740935; V3 antagonist - OrganonLatest Information Update: 16 Jul 2016
At a glance
- Originator Organon
- Developer Merck & Co; Sanofi
- Class
- Mechanism of Action Vasopressin 1b receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders; Major depressive disorder
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Anxiety-disorders in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Major depressive disorder in USA
- 13 Nov 2010 Preclinical trials in Anxiety disorders in USA